

Antonio Juan Ribelles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3670621/publications.pdf>

Version: 2024-02-01

17
papers

2,271
citations

933410

10
h-index

839512

18
g-index

18
all docs

18
docs citations

18
times ranked

2890
citing authors

#	ARTICLE	IF	CITATIONS
1	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 289-297.	1.6	1,540
2	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. <i>Journal of Clinical Oncology</i> , 2011, 29, 3286-3292.	1.6	248
3	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. <i>Lancet Oncology</i> , The, 2009, 10, 663-671.	10.7	176
4	Poor Survival for Infants With <i>MYCN</i> -Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. <i>Journal of Clinical Oncology</i> , 2009, 27, 1014-1019.	1.6	123
5	Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 410-420.	2.8	35
6	Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition. <i>Clinical Cancer Research</i> , 2017, 23, 6875-6887.	7.0	34
7	Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with <i>MYCN</i> Amplification Plus 11q Deletion. <i>PLoS ONE</i> , 2013, 8, e53740.	2.5	33
8	<i>MYCN</i> gain and <i>MYCN</i> amplification in a stage 4S neuroblastoma. <i>Cancer Genetics and Cytogenetics</i> , 2003, 140, 157-161.	1.0	30
9	Clinical Features of Neuroblastoma with 11q Deletion: An Increase in Relapse Probabilities in Localized and 4S Stages. <i>Scientific Reports</i> , 2019, 9, 13806.	3.3	15
10	Review: Ewing Sarcoma Predisposition. <i>Pathology and Oncology Research</i> , 2020, 26, 2057-2066.	1.9	11
11	Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care. <i>Cancers</i> , 2021, 13, 5339.	3.7	7
12	Metabolomic profiling in neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28113.	1.5	5
13	Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project. <i>Clinical and Translational Oncology</i> , 2018, 20, 1046-1052.	2.4	4
14	Paediatric tumour boards in Spain: a national survey. <i>Clinical and Translational Oncology</i> , 2016, 18, 931-936.	2.4	3
15	Distribution of segmental chromosomal alterations in neuroblastoma. <i>Clinical and Translational Oncology</i> , 2021, 23, 1096-1104.	2.4	3
16	Precision medicine in relapsed or refractory pediatric solid tumors: a collaborative Spanish initiative. <i>Translational Medicine Communications</i> , 2019, 4, .	1.4	2
17	Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas. <i>Journal of Personalized Medicine</i> , 2021, 11, 268.	2.5	1